BlueRock Therapeutics, a clinical-stage cell therapy company and subsidiary of Bayer, announced that it has exercised its option for an exclusive license to OpCT-001 for the treatment of primary photoreceptor diseases, from FUJIFILM Cellular Dynamics and Opsis.

' We believe that cell therapy has great potential to restore vision in patients with retinal diseases ', said Ahmed Enayetallah, Senior Vice President and Head of Development at BlueRock Therapeutics.

' Our collaboration with the FUJIFILM Cellular Dynamics team and Opsis Therapeutics has enabled us to execute important IND-enabling activities, and we are excited to advance OpCT-001 into the clinic, with an IND filing planned for this year. '

Primary photoreceptor diseases are a subgroup of inherited retinal disorders that include retinitis pigmentosa and cone dystrophies.

These diseases affect the structure and function of photoreceptor cells in the retina, leading to irreversible vision loss in children and adults. No treatment options currently exist for this patient population.

OpCT-001 aims to restore the vision loss caused by these diseases by replacing degenerated retinal tissue with functional cells.

Copyright (c) 2024 CercleFinance.com. All rights reserved.